Cancer Treatment Holdings, Inc.
CTHZ
OTC PK
| 02/28/2003 | 11/30/2002 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 134.43% | |||
| Total Other Revenue | -- | -16.33% | |||
| Total Revenue | -- | 68.18% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | 68.18% | |||
| SG&A Expenses | -61.44% | 111.66% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -60.30% | 107.36% | |||
| Operating Income | 57.19% | -111.33% | |||
| Income Before Tax | -125.62% | -111.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -125.62% | -111.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -125.62% | -111.33% | |||
| EBIT | 57.19% | -111.33% | |||
| EBITDA | 58.36% | -116.24% | |||
| EPS Basic | -125.71% | -111.41% | |||
| Normalized Basic EPS | 57.50% | -111.54% | |||
| EPS Diluted | -125.71% | -111.41% | |||
| Normalized Diluted EPS | 57.50% | -111.54% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
